Cholelithiasis
Conditions
Interventions
Experimental group:oral administration of Reduced Glutathione Tablets and Babaodan Jiaonang
Control group:oral Reduced Glutathione Tablets
Sponsors
Xiangya Hospital Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Cases of cholelithiasis after operation; 2. the assessment of liver function in decompensated state, without liver cirrhosis and portal hypertension patients; 3. According to the type of surgery: (1) laparoscopic choledocholithotomy +T tube drainage; (2) laparoscopic partial hepatectomy + choledochotomy and +T tube drainage; (3) open choledocholithotomy and +T tube drainage; (4) open surgical partial hepatectomy + choledochotomy and +T tube drainage; (5) choledochojejunostomy.;Inclusion criteria: 1. Cases of cholelithiasis after operation; 2. the assessment of liver function in decompensated state, without liver cirrhosis and portal hypertension patients; 3. According to the type of surgery: (1) laparoscopic choledocholithotomy +T tube drainage; (2) laparoscopic partial hepatectomy + choledochotomy and +T tube drainage; (3) open choledocholithotomy and +T tube drainage; (4) open surgical partial hepatectomy + choledochotomy and +T tube drainage; (5) choledochojejunostomy.
Exclusion criteria
Exclusion criteria: 1. Not conforming to the inclusion criteria; 2. Patients with severe primary diseases such as cardiovascular, cerebrovascular, liver, kidney and hematopoietic system; 3. Allergic constitution (allergic to two or more substances) or the composition of this drug to the allergy; 4. patients had the following one or more of: any unstable systemic disease (including active infection, poorly controlled hypertension, unstable angina and congestive heart failure, liver, kidney, or metabolic disease); It is not acceptable to take oral administration, require high energy nutrition in intravenous nutrition, and patients who have had previous effects on absorption, active digestive tract ulcer and chronic diarrhea; 5. The researchers believe that the subject may not be able to complete the study or be able to comply with the requirements of this study (for other reasons for management reasons).;Exclusion criteria: 1. Not conforming to the inclusion criteria; 2. Patients with severe primary diseases such as cardiovascular, cerebrovascular, liver, kidney and hematopoietic system; 3. Allergic constitution (allergic to two or more substances) or the composition of this drug to the allergy; 4. patients had the following one or more of: any unstable systemic disease (including active infection, poorly controlled hypertension, unstable angina and congestive heart failure, liver, kidney, or metabolic disease); It is not acceptable to take oral administration, require high energy nutrition in intravenous nutrition, and patients who have had previous effects on absorption, active digestive tract ulcer and chronic diarrhea; 5. The researchers believe that the subject may not be able to complete the study or be able to comply with the requirements of this study (for other reasons for management reasons).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Liver function;Blood coagulation function;Liver fibrosis five tests;CA199;Analysis of the composition of bile;;Liver function;Blood coagulation function;Liver fibrosis five tests;CA199;Analysis of the composition of bile; | — |
Countries
China
Contacts
Public ContactNianfeng Li;Nianfeng Li ;
Xiangya Hospital Central South University;Xiangya Hospital Central South University
Outcome results
None listed